TY - JOUR
T1 - Depression and Perceived Stress After Spontaneous Coronary Artery Dissection and Comparison With Other Acute Myocardial Infarction (the VIRGO Experience)
AU - Murugiah, Karthik
AU - Chen, Lian
AU - Dreyer, Rachel P.
AU - Bouras, Georgios
AU - Safdar, Basmah
AU - Lu, Yuan
AU - Spatz, Erica S.
AU - Gupta, Aakriti
AU - Khera, Rohan
AU - Ng, Vivian G.
AU - Bueno, Héctor
AU - Tweet, Marysia S.
AU - Spertus, John A.
AU - Hayes, Sharonne N.
AU - Lansky, Alexandra
AU - Krumholz, Harlan M.
N1 - Funding Information:
The VIRGO study was supported by a 4-year National Heart, Lung, and Blood Institute (Bethesda, Maryland) grant number 5R01HL081153. IMJOVEN was supported in Spain by grant PI 081614 from the Fondo de Investigaciones Sanitarias del Instituto Carlos III, Ministry of Science and Technology (Madrid, Spain), and additional funds from the Centro Nacional de Investigaciones Cardiovasculares (Madrid, Spain). The Centro Nacional de Investigaciones Cardiovasculares is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence, SEV-2015-0505. Dr. Murugiah is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (Bethesda, Maryland) under award 1K08HL157727. Dr Spatz receives support from the National Institute on Minority Health and Health Disparities, Bethesda, Maryland, U54MD010711-01, the National Heart, Lung, and Blood Institute, Bethesda, Maryland, and the US Food and Drug Administration, Silver Spring, Maryland, to support projects within the Yale-Mayo Clinic Center of Excellence in Regulatory Science and Innovation, New Haven, Connecticut.Dr. Bueno receives research funding from the Instituto de Salud Carlos III, Spain (PIE16/00021 and PI17/01799), Sociedad Española de Cardiología, Astra-Zeneca, Bayer, PhaseBio, and Novartis; has received consulting fees from Astra-Zeneca, Novartis, and Organon; speaking fees from Novartis, and is a scientific advisor for MEDSCAPE-the heart.org. In the past 3 years, Dr. Krumholz received expenses and/or personal fees from UnitedHealth, Element Science, Aetna, Reality Labs, Tesseract/4Catalyst, F-Prime, the Siegfried and Jensen Law Firm, Arnold and Porter Law Firm, and Martin/Baughman Law Firm. He is a co-founder of Refactor Health and HugoHealth, and is associated with contracts, through Yale New Haven Hospital, with the Centers for Medicare & Medicaid Services and through Yale University with Johnson & Johnson. The remaining authors have no conflicts of interest to declare.
Funding Information:
The VIRGO study was supported by a 4-year National Heart, Lung, and Blood Institute (Bethesda, Maryland) grant number 5R01HL081153 . IMJOVEN was supported in Spain by grant PI 081614 from the Fondo de Investigaciones Sanitarias del Instituto Carlos III, Ministry of Science and Technology (Madrid, Spain) , and additional funds from the Centro Nacional de Investigaciones Cardiovasculares (Madrid, Spain) . The Centro Nacional de Investigaciones Cardiovasculares is supported by the Instituto de Salud Carlos III (ISCIII) , the Ministerio de Ciencia e Innovación and the Pro CNIC Foundation , and is a Severo Ochoa Center of Excellence , SEV-2015-0505 . Dr. Murugiah is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (Bethesda, Maryland) under award 1K08HL157727 . Dr Spatz receives support from the National Institute on Minority Health and Health Disparities, Bethesda, Maryland , U54MD010711-01 , the National Heart, Lung, and Blood Institute, Bethesda, Maryland , and the US Food and Drug Administration, Silver Spring, Maryland , to support projects within the Yale-Mayo Clinic Center of Excellence in Regulatory Science and Innovation, New Haven, Connecticut.
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/6/15
Y1 - 2022/6/15
N2 - Data on depression and stress among patients with spontaneous coronary artery dissection (SCAD) are limited. Using data from the VIRGO (Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients) study, which prospectively enrolled 3,572 acute myocardial infarction (AMI) patients between 18 and 55 years of age, we identified 67 SCAD cases. We compared Patient Health Questionnaire-9 (PHQ-9) and 14-item Perceived Stress Scale (PSS-14) scores obtained at baseline, 1 month, and 12 months between SCAD and AMI of all other causes. Using longitudinal linear mixed-effects analysis, we compared depression and stress scores between SCAD and other AMI, adjusting for time and selected covariates. Patients with SCAD had lower baseline PHQ-9 scores (6.1 ± 6.0 vs 7.7 ± 6.4 for other patients with AMI, p = 0.03), similar 1-month scores, and lower 12-month scores (3.2 ± 4.3 vs 4.9 ± 5.5, p = 0.004). At baseline and 1 month, patients with SCAD had similar PSS-14 scores to those of other patients with AMI. At 12 months, patients with SCAD had lower scores (18.4 ± 8.8 vs 21.5 ± 9.3 for other patients with AMI, p = 0.009). After adjustment for cardiovascular risk factors, co-morbidities, and clinical acuity, no differences in PHQ-9 or PSS-14 scores remained between SCAD and other AMI. Similar results were obtained in a subgroup analysis of only women with SCAD and other AMI. In conclusion, patients with SCAD had a relatively lower burden of depression and perceived stress than other patients with AMI, potentially because of fewer co-morbidities and favorable socioeconomic factors. However, given high depression and stress burden in both SCAD and other patients with AMI, routine screening can help identify and treat these patients.
AB - Data on depression and stress among patients with spontaneous coronary artery dissection (SCAD) are limited. Using data from the VIRGO (Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients) study, which prospectively enrolled 3,572 acute myocardial infarction (AMI) patients between 18 and 55 years of age, we identified 67 SCAD cases. We compared Patient Health Questionnaire-9 (PHQ-9) and 14-item Perceived Stress Scale (PSS-14) scores obtained at baseline, 1 month, and 12 months between SCAD and AMI of all other causes. Using longitudinal linear mixed-effects analysis, we compared depression and stress scores between SCAD and other AMI, adjusting for time and selected covariates. Patients with SCAD had lower baseline PHQ-9 scores (6.1 ± 6.0 vs 7.7 ± 6.4 for other patients with AMI, p = 0.03), similar 1-month scores, and lower 12-month scores (3.2 ± 4.3 vs 4.9 ± 5.5, p = 0.004). At baseline and 1 month, patients with SCAD had similar PSS-14 scores to those of other patients with AMI. At 12 months, patients with SCAD had lower scores (18.4 ± 8.8 vs 21.5 ± 9.3 for other patients with AMI, p = 0.009). After adjustment for cardiovascular risk factors, co-morbidities, and clinical acuity, no differences in PHQ-9 or PSS-14 scores remained between SCAD and other AMI. Similar results were obtained in a subgroup analysis of only women with SCAD and other AMI. In conclusion, patients with SCAD had a relatively lower burden of depression and perceived stress than other patients with AMI, potentially because of fewer co-morbidities and favorable socioeconomic factors. However, given high depression and stress burden in both SCAD and other patients with AMI, routine screening can help identify and treat these patients.
UR - http://www.scopus.com/inward/record.url?scp=85128277885&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128277885&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2022.03.005
DO - 10.1016/j.amjcard.2022.03.005
M3 - Article
C2 - 35365290
AN - SCOPUS:85128277885
SN - 0002-9149
VL - 173
SP - 33
EP - 38
JO - American Journal of Cardiology
JF - American Journal of Cardiology
ER -